文献速递胸部肿瘤放疗放疗物理与技术

筛查人群中Ⅰ期肺癌的根治性放疗:I-ELCAP研究结果

Definitive Radiation for Stage I Lung Cancer in a Screened Population: Results From the I-ELCAP.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-01-22

国际早期肺癌行动计划队列研究比较临床Ⅰ期非小细胞肺癌根治性放疗与手术切除的特征和结局,放疗组肺癌特异性生存率90.0%与手术组94.8%无显著差异(P=0.09),放疗组中位随访4.3年短于手术组10.0年(P<0.0001),作者认为放疗似乎是筛查诊断肺癌患者手术的可行替代方案。

要点

  • 853例临床Ⅰ期非小细胞肺癌中31例(3.6%)接受根治性放疗,702例(82.3%)仅接受手术切除。
  • 放疗组肺癌特异性生存率90.0%(95%CI 84.9%-100.0%)与手术组94.8%(95%CI 93.0%-96.6%)无显著差异(P=0.09)。
  • 放疗组中位随访4.3年短于手术组10.0年(P<0.0001)。

核心结论

  • 尽管放疗组患者年龄更大且合并症更多,其肺癌特异性长期生存率与仅接受手术者无显著差异(P=0.09)。
  • 作者认为,对于筛查诊断的肺癌患者,放疗似乎是手术的可行替代方案。

研究设计与样本

  • 国际早期肺癌行动计划(I-ELCAP)队列研究,数据来自1992年至2017年数据库。
  • 在82628次基线筛查和109250次年度重复筛查中,853例诊断为临床Ⅰ期非小细胞肺癌。
  • 31例(3.6%)接受根治性放疗,702例(82.3%)仅接受手术切除;放疗计划由患者所在机构决定。
  • 随访时间从诊断计算至肺癌死亡、失访或2017年12月31日,以先发生者为准。

主要发现

  • 31例放疗患者中24例可获得放疗处方信息:中位剂量54.5 Gy,中位分次数5次,17例接受立体定向体部放疗。
  • 放疗组肺癌特异性生存率90.0%(95%CI 84.9%-100.0%)vs 手术组94.8%(95%CI 93.0%-96.6%),P=0.09。
  • 全体中位随访时间9.7年,放疗组4.3年短于手术组10.0年(P<0.0001)。

临床怎么用

  • 作者认为,对于筛查诊断的肺癌患者,放疗似乎是手术的可行替代方案。

局限性

  • 放疗组中位随访时间4.3年短于手术组10.0年(P<0.0001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The International Early Lung Cancer Action Program is a cohort study to assess the cure rate of participants undergoing annual low-dose computed tomography screening for lung cancer. This study compares the characteristics and outcomes of patients who received a diagnosis of clinical stage I non-small cell lung carcinoma (NSCLC) treated with definitive radiation therapy and surgical resection. METHODS AND MATERIALS: Patient information was drawn from the International Early Lung Cancer Action Program database from 1992 to 2017. All instances in which treatment was performed for histologically proven stage I NSCLC using definitive radiation therapy and surgery were identified. The home institution determined radiation plans. Patient characteristics and Kaplan-Meier lung cancer-specific (LCS) long-term survival rates were compared for both types of treatment. Follow-up time was calculated from time of diagnosis until death from lung cancer, loss to follow-up, or December 31, 2017, whichever came earlier. RESULTS: Among 82,628 baseline and 109,250 annual repeat screenings, 853 patients received a diagnosis of clinical stage I NSCLC, of whom 31 (3.6%) were treated by definitive radiation therapy and 702 (82.3%) by surgical resection alone. Radiation therapy prescription information was obtainable for 24 of the 31 patients: The median dose was 54.5 Gy, the median number of fractions was 5, and 17 patients were treated using stereotactic body radiation therapy. LCS survival rates were not significantly different for radiation therapy compared with surgery: 90.0% (95% confidence interval, 84.9%-100.0%) versus 94.8% (95% confidence interval, 93.0%-96.6%) (P = .09). Median follow-up time was 9.7 years for all, but it was shorter for those treated by radiation therapy than for those who underwent surgery (4.3 vs 10.0 years, P < .0001). CONCLUSIONS: The majority of patients identified by computed tomography screening were treated with surgical resection. Despite being older and having more comorbidities, LCS long-term survival rates of patients treated with definitive radiation therapy were not significantly different compared with survival rates of patients treated with surgery alone. Radiation therapy appears to be a viable alternative to surgery for screen-diagnosed patients with lung cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Berlin E, Buckstein M, Yip R, et al. Definitive Radiation for Stage I Lung Cancer in a Screened Population: Results From the I-ELCAP. Int J Radiat Oncol Biol Phys. 2019. PMID: 30677471. doi:10.1016/j.ijrobp.2019.01.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。